Notably, the combination of rociletinib and crizotinib was also able to restore activity of rociletinib in a patient-derived NSCLC xenograft model that harbours an EGFR L858R activating mutation and 14-copy amplification of MET (Fig. 8; Supplementary Fig. 5). This evidence concerns the gene EGFR and non-small cell lung carcinoma.